SHORT-TERM TREATMENT OUTCOMES OF FORREST IIB GASTRIC AND DUODENAL ULCER BLEEDING USING HIGH-DOSE INTRAVENOUS NEXIUM

Background: Among the causes of upper gastrointestinal bleeding, gastric and duodenal ulcers (GDU) are the most common. Forrest classification IIB (FIIB) is assessed as having a high risk of recurrent bleeding as FIA, FIB, FIIA, but treatment opinions differ. As of 2021, the European Society of Gastrointestinal Endoscopy recommends considering high-dose PPI treatment for patients in the FIIB group without endoscopic hemostasis as strong recommendation, high level of evidence. Objectives: To describe clinical and laboratory characteristics. To evaluate the short-term treatment outcomes of FIIB GDU bleeding using high-dose intravenous Nexium. Materials and methods: An uncontrolled clinical trial was conducted with 41 patients diagnosed gastrointestinal bleeding due to FIIB GDU admitted to Can Tho Central General Hospital from June 2022 to May 2024. Results: The research shows that the majority of patients responded well to treatment with high-dose intravenous Nexium (85.4%). The rates of rebleeding, surgical intervention, and mortality were relatively low at 7.3%, 2.4%, and 4.9%, respectively. Cumulative treatment failure risk was approximately 5% after 6 days of hospitalization and increased to 12.5% after 20 days of treatment. Conclusion: In patients with gastrointestinal bleeding due to FIIB peptic ulcers, treatment with high-dose intravenous Nexium has a relatively high success rate in short-term outcomes during hospitalization.